165 related articles for article (PubMed ID: 6259323)
1. Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor.
Sweet CS; Gross DM; Arbegast PT; Gaul SL; Britt PM; Ludden CT; Weitz D; Stone CA
J Pharmacol Exp Ther; 1981 Mar; 216(3):558-66. PubMed ID: 6259323
[No Abstract] [Full Text] [Related]
2. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological properties of the converting enzyme inhibitor, enalapril maleate (MK-421).
Sweet CS
Fed Proc; 1983 Feb; 42(2):167-70. PubMed ID: 6295819
[TBL] [Abstract][Full Text] [Related]
4. Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.
Biollaz J; Brunner HR; Gavras I; Waeber B; Gavras H
J Cardiovasc Pharmacol; 1982; 4(6):966-72. PubMed ID: 6185790
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive profile of the angiotensin-converting enzyme inhibitors CI-906 and CI-907.
Ryan MJ; Boucher DM; Cohen DM; Olszewski BJ; Singer RM; Smith RD; Kaplan HR
Fed Proc; 1984 Apr; 43(5):1330-2. PubMed ID: 6323224
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
Lebel M; Rodrigue ME; Agharazii M; Larivière R
Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
[TBL] [Abstract][Full Text] [Related]
7. Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats.
Sweet CS; Arbegast PT; Gaul SL; Blaine EH; Gross DM
Eur J Pharmacol; 1981 Dec; 76(2-3):167-76. PubMed ID: 6174351
[TBL] [Abstract][Full Text] [Related]
8. Hemodynamic effects of new angiotensin converting enzyme inhibitors during continuous angiotensin I infusion on conscious dogs.
Hütter JF; Dehn A; Schmidt W
Arzneimittelforschung; 1988 Jul; 38(7):896-901. PubMed ID: 2849951
[TBL] [Abstract][Full Text] [Related]
9. Correlation between angiotensin converting enzyme inhibition and the acute hypotensive response to MK 421 in essential hypertension.
Jackson B; McGrath BP; Johnston CI
Clin Exp Pharmacol Physiol Suppl; 1982; 7():99-104. PubMed ID: 6291832
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models.
Nagata S; Takeyama K; Fukuya F; Nagai R; Hosoki K; Nishimura K; Deguchi T; Karasawa T
Arzneimittelforschung; 1995 Aug; 45(8):853-8. PubMed ID: 7575746
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic and antihypertensive effects of the new oral angiotensin-converting-enzyme inhibitor MK-421 (enalapril).
Fouad FM; Tarazi RC; Bravo EL; Textor SC
Hypertension; 1984; 6(2 Pt 1):167-74. PubMed ID: 6327515
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive, hemodynamic and autonomic profile of a new angiotensin converting enzyme inhibitor, SCH 33844 (spirapril).
Baum T; Watkins RW; Sybertz EJ; Ahn HS; Nelson S; Coleman W; Tedesco R; Pula KK; Rivelli M; Sabin C
Arch Int Pharmacodyn Ther; 1987 Apr; 286(2):230-45. PubMed ID: 2884941
[TBL] [Abstract][Full Text] [Related]
13. Relation of plasma renin activity to the antihypertensive effect of MK 421 in the rat.
Bradshaw D; Franz PH; Sugden AL
Br J Pharmacol; 1982 May; 76(1):163-8. PubMed ID: 6282372
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
15. Effects of captopril and enalapril on sodium excretion and blood pressure in sodium-deficient dogs.
McCaa RE; Gillespie JB
Fed Proc; 1984 Apr; 43(5):1336-41. PubMed ID: 6323226
[TBL] [Abstract][Full Text] [Related]
16. Effects of angiotensin-converting-enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide-deficiency-induced hypertension in rats.
García-Estañ J; Ortiz MC; O'Valle F; Alcaraz A; Navarro EG; Vargas F; Evangelista S; Atucha NM
Clin Sci (Lond); 2006 Feb; 110(2):227-33. PubMed ID: 16197366
[TBL] [Abstract][Full Text] [Related]
17. Effect of an orally active renin inhibitor Cl-992 on blood pressure in normotensive and hypertensive monkeys.
Ryan MJ; Hicks GW; Batley BL; Rapundalo ST; Patt WC; Taylor DG; Keiser JA
J Pharmacol Exp Ther; 1994 Jan; 268(1):372-9. PubMed ID: 8301578
[TBL] [Abstract][Full Text] [Related]
18. CI-906 and CI-907: new orally active nonsulfhydryl angiotensin-converting enzyme inhibitors.
Kaplan HR; Cohen DM; Essenburg AD; Major TC; Mertz TE; Ryan MJ
Fed Proc; 1984 Apr; 43(5):1326-9. PubMed ID: 6323223
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the inhibitory effect of N(G)-nitro-L-arginine methyl ester on the antihypertensive effect of the angiotensin AT1 receptor antagonist, GR138950.
Anderson IK; Drew GM
Br J Pharmacol; 1997 Dec; 122(7):1385-94. PubMed ID: 9421286
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Becker RH; Schölkens BA; Metzger M; Schulze KJ
Arzneimittelforschung; 1984; 34(10B):1411-6. PubMed ID: 6097267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
